H A Wakelee

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Aflibercept in lung cancer
    Joel W Neal
    Stanford University Stanford Cancer Institute, Department of Medicine Oncology, Stanford, CA, USA
    Expert Opin Biol Ther 13:115-20. 2013
  2. pmc A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501
    Heather A Wakelee
    Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA
    J Thorac Oncol 7:1574-82. 2012
  3. pmc A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Sukhmani K Padda
    Department of Medicine, Division of Oncology, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    Cancer Chemother Pharmacol 69:1013-20. 2012
  4. pmc Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab
    H A Wakelee
    Department of Medicine Division of Oncology, Stanford University, Stanford, CA, USA
    Lung Cancer 76:410-5. 2012
  5. doi request reprint A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
    Heather A Wakelee
    Division of Oncology, Department of Medicine, Stanford University and Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    Cancer Chemother Pharmacol 69:815-24. 2012
  6. ncbi request reprint Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594
    Heather A Wakelee
    Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305 5826, USA
    J Thorac Oncol 1:441-6. 2006
  7. ncbi request reprint Novel approaches for the treatment of small cell lung cancer
    Heather Wakelee
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Hematol Oncol Clin North Am 18:499-518. 2004
  8. doi request reprint Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer
    Heather Wakelee
    Department of Medicine, Division of Oncology, Stanford Cancer Center, Stanford, California 94305 5826, USA
    Clin Lung Cancer 9:9-15. 2008
  9. doi request reprint Antibodies to vascular endothelial growth factor in non-small cell lung cancer
    Heather Wakelee
    Department of Medicine, Division of Oncology, Stanford University, Stanford Cancer Center, Stanford, California 94305 5826, USA
    J Thorac Oncol 3:S113-8. 2008
  10. doi request reprint Adjuvant chemotherapy for resected non-small cell lung cancer
    Heather Wakelee
    Department of Medicine Oncology, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
    Semin Thorac Cardiovasc Surg 20:198-203. 2008

Collaborators

Detail Information

Publications40

  1. doi request reprint Aflibercept in lung cancer
    Joel W Neal
    Stanford University Stanford Cancer Institute, Department of Medicine Oncology, Stanford, CA, USA
    Expert Opin Biol Ther 13:115-20. 2013
    ..Aflibercept (VEGF Trap) is a recombinant VEGF receptor-antibody protein fusion with higher affinity for VEGF-A than bevacizumab, plus affinity for VEGF-B and placental growth factor (PlGF)...
  2. pmc A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501
    Heather A Wakelee
    Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA
    J Thorac Oncol 7:1574-82. 2012
    ..Sorafenib is a raf kinase and angiogenesis inhibitor with activity in multiple cancers. This phase-II study in heavily pretreated non-small-cell lung cancer (NSCLC) patients (≥ 2 prior therapies) used a randomized discontinuation design...
  3. pmc A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Sukhmani K Padda
    Department of Medicine, Division of Oncology, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    Cancer Chemother Pharmacol 69:1013-20. 2012
    ..Erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, has activity in solid tumors. Based on the promising combination of EGFR inhibitors and anti-angiogenic agents, this phase I trial was initiated...
  4. pmc Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab
    H A Wakelee
    Department of Medicine Division of Oncology, Stanford University, Stanford, CA, USA
    Lung Cancer 76:410-5. 2012
    ..The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex...
  5. doi request reprint A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
    Heather A Wakelee
    Division of Oncology, Department of Medicine, Stanford University and Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    Cancer Chemother Pharmacol 69:815-24. 2012
    ..This study looked for pharmacokinetic (PK) interactions between the agents in parallel with a phase III study of the combination...
  6. ncbi request reprint Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594
    Heather A Wakelee
    Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305 5826, USA
    J Thorac Oncol 1:441-6. 2006
    ..E1594 randomized patients with advanced NSCLC to one of four platinum doublets and found that all four regimens had comparable efficacy...
  7. ncbi request reprint Novel approaches for the treatment of small cell lung cancer
    Heather Wakelee
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Hematol Oncol Clin North Am 18:499-518. 2004
  8. doi request reprint Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer
    Heather Wakelee
    Department of Medicine, Division of Oncology, Stanford Cancer Center, Stanford, California 94305 5826, USA
    Clin Lung Cancer 9:9-15. 2008
    ..Ongoing trials within the cooperative groups continue to drive steady improvement in the treatment of lung cancer and offer great promise for the future...
  9. doi request reprint Antibodies to vascular endothelial growth factor in non-small cell lung cancer
    Heather Wakelee
    Department of Medicine, Division of Oncology, Stanford University, Stanford Cancer Center, Stanford, California 94305 5826, USA
    J Thorac Oncol 3:S113-8. 2008
    ..Exploration of the safety and efficacy of the drug in combination with other chemotherapeutics and targeted agents, and in previously excluded patient populations such as those with brain metastases, is also ongoing...
  10. doi request reprint Adjuvant chemotherapy for resected non-small cell lung cancer
    Heather Wakelee
    Department of Medicine Oncology, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
    Semin Thorac Cardiovasc Surg 20:198-203. 2008
    ..Other studies looking at tumor gene and protein expression will lead us toward better identification of patients most likely to benefit from therapy...
  11. doi request reprint Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer
    Heather Wakelee
    Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA 94305, USA
    Clin Lung Cancer 9:346-51. 2008
    ..Ongoing trials within the cooperative groups are an essential component of the persistent improvement in the treatment of lung cancer...
  12. pmc Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
    H A Wakelee
    Department of Medicine Oncology, Stanford University, Stanford, CA 94305 5826, USA
    Ann Oncol 21:376-81. 2010
    ..Materials and methods: This phase 1, dose escalation study assessed the safety, tolerability, pharmacokinetics (PKs) and immunogenicity of lexatumumab administered i.v. every 14 days in patients with advanced solid tumors...
  13. doi request reprint Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress
    Heather Wakelee
    Department of Medicine, Division of Oncology, Stanford University Cancer Center, Stanford, CA 94305 5826, USA
    Clin Lung Cancer 10:395-404. 2009
    ....
  14. doi request reprint The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer
    Heather A Wakelee
    Division of Oncology, Department of Medicine, Stanford University and Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    Cancer Chemother Pharmacol 69:563-71. 2012
    ..This trial was run in parallel with phase III trials of the combinations to determine whether repeated doses of bexarotene capsules affect the pharmacokinetics (PK) of the chemotherapeutic or the lipid-lowering agents...
  15. ncbi request reprint Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease
    Heather Wakelee
    Oncology, Stanford University, 875 Blake Wilbur Drive, Room 2233, Stanford, California 94305 5826, USA
    Oncologist 12:331-7. 2007
    ..Strategies such as inhibition of angiogenesis pathways and the epidermal growth factor receptor are under exploration...
  16. pmc Lung cancer incidence in never smokers
    Heather A Wakelee
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, USA
    J Clin Oncol 25:472-8. 2007
    ..However, data on this topic, particularly lung cancer incidence rates in never smokers, are limited...
  17. ncbi request reprint Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group
    Heather A Wakelee
    Stanford Clinical Cancer Center, 875 Blake Wilbur Drive, Room 2231, Stanford, CA 94305 5826, USA
    Lung Cancer 48:389-97. 2005
    ..The risk of DID following resection of stages II and IIIA NSCLC is not increased in patients who received PORT or CPORT...
  18. ncbi request reprint Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990
    Heather A Wakelee
    Department of Medicine, Division of Medical Oncology, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
    Cancer 106:2208-17. 2006
    ....
  19. ncbi request reprint Second- and third-line treatments in non-small cell lung cancer
    Atul Kumar
    Stanford Cancer Center, Stanford, CA 94305, USA
    Curr Treat Options Oncol 7:37-49. 2006
    ....
  20. ncbi request reprint Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors
    Heather A Wakelee
    Oncology Division, Stanford University School of Medicine, CA, USA
    Clin Lung Cancer 7:S6-12. 2005
    ..Gimatecan and other novel camptothecins have superior preclinical activity and promising phase I/II data in NSCLC and SCLC...
  21. ncbi request reprint Docetaxel in advanced non-small cell lung cancer
    Heather Wakelee
    Stanford University School of Medicine, Stanford University Cancer Center, 875 Blake Wilbur Dr, Stanford, CA 94305 5826, USA
    Expert Rev Anticancer Ther 5:13-24. 2005
    ..This article reviews recent studies of docetaxel as a single agent and in combination regimens with cytotoxic and more recent targeted agents in the management of advanced NSCLC...
  22. ncbi request reprint A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer
    Heather Wakelee
    Stanford Clinical Cancer Center, Stanford, CA 94305 5826, USA
    Invest New Drugs 23:241-2. 2005
  23. ncbi request reprint Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial
    Heather A Wakelee
    Stanford Cancer Center, CA 94305 5826, USA
    Clin Lung Cancer 8:18-21. 2006
    ..Because of the recent update, this trial will now limit patients with stage IB disease to those with larger tumors (>or= 4 cm) and will likely include only cisplatin-based regimens...
  24. ncbi request reprint Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors
    Elwyn Cabebe
    Stanford University, Stanford Cancer Center, Stanford 94305 5826, USA
    Curr Treat Options Oncol 8:15-27. 2007
    ..We can hope that further improvements in survival will follow...
  25. ncbi request reprint Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors
    Quynh Thu Le
    Department of Radiation Oncology, Stanford University, Stanford, California, USA
    J Thorac Oncol 1:802-9. 2006
    ..The purpose of this study was to report initial results of a phase I study using single-fraction stereotactic radiotherapy (RT) in patients with inoperable lung tumors...
  26. doi request reprint Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: a review
    Christelle Clément-Duchêne
    Division of Medical Oncology, Stanford Clinical Cancer Center, Stanford, California 94305 5826, USA
    J Thorac Oncol 5:129-39. 2010
    ..This article will review these new targeted antiangiogenic and antivascular agents with a focus on their use as lung cancer therapeutics...
  27. ncbi request reprint Sunitinib: a newly approved small-molecule inhibitor of angiogenesis
    Elwyn Cabebe
    Division of Medical Oncology, Stanford University, Stanford, California 94305, USA
    Drugs Today (Barc) 42:387-98. 2006
    ....
  28. ncbi request reprint An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers
    Quynh Thu Le
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305 5847, USA
    Clin Cancer Res 12:1507-14. 2006
    ..To directly assess tumor oxygenation in resectable non-small cell lung cancers (NSCLC) and to correlate tumor pO2 and the selected gene and protein expression to treatment outcomes...
  29. ncbi request reprint Optimizing first-line treatment options for patients with advanced NSCLC
    Heather Wakelee
    Stanford University, Stanford, California, USA
    Oncologist 10:1-10. 2005
    ..Each incremental advance demonstrates that progress can be made in first-line treatment of advanced NSCLC...
  30. doi request reprint Pemetrexed disodium for the treatment of NSCLC: an update
    Jerry Y Hsu
    Division of Medical Oncology, Stanford University, Stanford, California 94305 5826, USA
    Drugs Today (Barc) 44:669-78. 2008
    ..Pemetrexed is currently being tested in clinical trials as part of second-line combination, first-line, adjuvant and maintenance therapies...
  31. doi request reprint Complications of ablative therapies in lung cancer
    Sukhmani Padda
    Department of Medicine, Stanford University, Stanford, CA, USA
    Clin Lung Cancer 9:122-6. 2008
    ..These cases highlight the caution that should still be observed when recommending lung ablation strategies and the importance of selecting appropriate patients...
  32. ncbi request reprint AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer
    Joel Neal
    Stanford University Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    Curr Opin Mol Ther 12:487-95. 2010
    ..If safe and effective, AMG-386 could be an exciting addition to other antiangiogenic therapies in solid tumors...
  33. doi request reprint Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy
    Thomas J Lynch
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 3:S107-12. 2008
    ..A CME activity based on this summary is also available at www.informedicalcme.com/cme...
  34. ncbi request reprint Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response
    Jessica S Donington
    Department of Cardiothoracic Surgery, Stanford University School of Medicine, CA 94303, USA
    Clin Lung Cancer 8:22-9. 2006
    ..Several phase II trials with small-molecule inhibitors of Src are under way or have been initiated in lung cancer and in other malignancies, as discussed herein...
  35. ncbi request reprint Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer
    Heather A Wakelee
    Oncology Division, Stanford University School of Medicine, CA, USA
    Clin Lung Cancer 7:S31-8. 2005
    ..We present phase I data (and phase II/III data when available) of these compounds and discuss their potential development in the treatment of lung cancer...
  36. ncbi request reprint Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer
    Timothy Kuo
    Oncology Division, Department of Medicine, Stanford University School of Medicine, 269 Campus Dr, CCSR 1105, Stanford, CA 94305 5151, USA
    J Clin Oncol 23:5613-9. 2005
    ..To investigate the gefitinib, fluorouracil (FU), leucovorin, and oxaliplatin regimen (IFOX) in previously treated patients with metastatic colorectal cancer...
  37. ncbi request reprint Sex differences in lung-cancer susceptibility: a smoke screen?
    Heather A Wakelee
    Lancet Oncol 9:609-10. 2008
  38. ncbi request reprint A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma
    Millie S Roy
    Department of Medicine, Stanford University School of Medicine, CA, USA
    Clin Lung Cancer 8:146-8. 2006
    ....
  39. doi request reprint Lung cancer presenting with amegakaryocytic thrombocytopenia
    Wesley H Witteles
    Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 26:1171-4. 2008
  40. ncbi request reprint Metabolic tumor burden predicts for disease progression and death in lung cancer
    Percy Lee
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305 5847, USA
    Int J Radiat Oncol Biol Phys 69:328-33. 2007
    ..However, stage may be simply a surrogate for underlying tumor burden. Our purpose was to assess the prognostic value of tumor burden measured by 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging...